Atherosclerotic Cardiovascular Disease, Vascular Disease
Conditions
Keywords
Vascular Diseases, Lipids, Cholesteryl Ester Transfer Protein (CETP) Inhibition, Anacetrapib, Cardiovascular Disease, Cholesterol
Brief summary
There are currently no studies evaluating the effect of anacetrapib on blood vessel function and stiffness of the arteries. The REVEAL-Vasc trial will assess whether anacetrapib, in addition to atorvastatin (LDL-C lowering drug) treatment, results in greater endothelial-dependent vascular function and aortic stiffness in patients with established cardiovascular disease, compared to adding placebo. Participants will be asked to provide a blood sample and pulse Wave Velocity/Pulse Wave Analysis and Flow Mediated Dilation will be carried out to assess blood vessel function and stiffness of the arteries. REVEAL-Vasc is an investigator led sub-study of HPS3/TIMI 55: REVEAL (Randomized Evaluation of the Effects of Anacetrapib through Lipid modification): A large-scale, randomized placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease (NCT01252953) which is coordinated by OXFORD CTSU. No treatment will be received on this sub-study, therefore only participants who have been enrolled in HPS3/TIMI55 REVEAL in which participants received anacetrapib with atorvastatin or placebo will be considered for this trial.
Detailed description
REVEAL-Vasc is an investigator led sub-study of HPS3/TIMI 55: REVEAL. Participants who previously enrolled on HPS3/TIMI 55: REVEAL and received treatment will be invited to participate in this sub-study. Participants will attend a screening and an assessment visit during which Pulse Wave Velocity/ Pulse Wave Analysis and Flow Mediated Dilation will be carried out to assess blood vessel function and stiffness. A blood sample will also be taken from participant to assess CRP and lipid profile. Since participants will have received treatment on the main trial HPS3/TIMI 55: REVEAL, no treatment will be received on this sub-study.
Interventions
DRUGAnacetrapib
No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
DRUGStatin
No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
DRUGPlacebo
No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
Sponsors
British Heart Foundation Cambridge Centre of Excellence
Cambridge University Hospitals NHS Foundation Trust
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participants who have been randomised into the HPS3/TIMI 55- REVEAL study (NCT01252953)
Exclusion criteria
* Any concomitant condition that, at the discretion of the investigator, may affect the participant's ability to complete the study or study procedures * Atrial fibrillation at time of assessment * Inability to provide informed consent * Inability to refrain from caffeine containing products for 6 hours prior to study visit * Inability to refrain from smoking for 2 hours prior to study visit
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The effect of treatment on flow-mediated dilation (FMD) | Visits 0-1 (day 0 up to approximately day 28 depending on scheduling of visits) | Measured by FMD as a surrogate measure of endothelial-dependent vasodilation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The effect of treatment on aortic (carotid-to-femoral) Pulse Wave Velocity (PWV) | Visits 0-1 (day 0 up to approximately day 28 depending on scheduling of visits) | Measured by PWV as a surrogate measure of aortic stiffness |
| The effect of treatment on central blood pressure | Visits 0-1 (day 0 up to approximately day 28 depending on scheduling of visits) | As a measure of central haemodynamics |
| The effect of treatment on sublingual glyceryl trinitrate (GTN) response on artery dilation | Visits 0-1 (day 0 up to approximately day 28 depending on scheduling of visits) | Measured by FMD as a surrogate measure of endothelial-independent vasodilation |
Other
| Measure | Time frame | Description |
|---|---|---|
| The analysis of low density lipoproteins, high density lipoproteins, total cholesterol and triglycerides (amongst other analytes) from collected blood samples | Visits 0-1 (day 0 up to approximately day 28 depending on scheduling of visits) | As a measure of treatment on lipid profile |
Countries
United Kingdom
Outcome results
None listed